Swipe om te navigeren naar een ander artikel
We conducted a pilot randomized controlled trial to determine the feasibility and initial safety and efficacy of omega-3 fatty acids (1.3 g/day) for the treatment of hyperactivity in 27 children ages 3–8 with autism spectrum disorder (ASD). After 12 weeks, hyperactivity, as measured by the Aberrant Behavior Checklist, improved 2.7 (±4.8) points in the omega-3 group compared to 0.3 (±7.2) points in the placebo group (p = 0.40; effect size = 0.38). Correlations were found between decreases in five fatty acid levels and decreases in hyperactivity, and the treatment was well tolerated. Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
Bell, J. G., MacKinlay, E. E., Dick, J. R., MacDonald, D. J., Boyle, R. M., & Glen, A. C. (2004). Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukotrienes and Essential Fatty Acids, 71(4), 201–204. CrossRef
Bent, S., Bertoglio, K., & Hendren, R. L. (2009). Omega-3 fatty acids for autistic spectrum disorder: A systematic review. Journal of Autism and Developmental Disorders, 39(8), 1135–1154. CrossRef
Bu, B., Ashwood, P., Harvey, D., King, I. B., Water, J. V. D., & Jin, L. W. (2006). Fatty acid compositions of red blood cell phospholipids in children with autism. Prostaglandins Leukotrienes and Essential Fatty Acids, 74(4), 215–221. CrossRef
Goin-Kochel, R. P., Myers, B. J., & Mackintosh, V. H. (2007). Parental reports on the use of treatments and therapies for children with autism spectrum disorders. Research in Autism Spectrum Disorders, 1(3), 195–209. CrossRef
McDowell, I., & Newell, C. (1996). Measuring health: A guide to rating scales and questionnaires. New York, NY: Oxford University Press.
Patrick, L., & Salik, R. (2005). The effect of essential fatty acid supplementation on language development and learning skills in Autism and Asperger’s Syndrome. Autism Asperger’s Digest, 36–37.
Savitz, D. A., & Olshan, A. F. (1998). Describing data requires no adjustment for multiple comparisons: A reply from Savitz and Olshan. American Journal of Epidemiology, 147(9), 813–814. discussion 815. PubMed
Schachter, H. M., Kourad, K., Merali, Z., Lumb, A., Tran, K., & Miguelez, M. (2005). Effects of omega-3 fatty acids on mental health. Evidence Report/Technology Assessment (Summary), 116, 1–11.
Simopoulos, A. P. (2002). Omega-3 fatty acids in inflammation and autoimmune diseases. Journal of the American College of Nutrition, 21(6), 495–505. PubMed
Thompson, J. R. (1998). Invited commentary: Re: “Multiple comparisons and related issues in the interpretation of epidemiologic data”. American Journal of Epidemiology, 147(9), 801–806. PubMed
Vancassel, S., Durand, G., Barthelemy, C., Lejeune, B., Martineau, J., Guilloteau, D., et al. (2001). Plasma fatty acid levels in autistic children. Prostaglandins Leukotrienes and Essential Fatty Acids, 65(1), 1–7. CrossRef
Wiest, M. M., German, J. B., Harvey, D. J., Watkins, S. M., & Hertz-Picciotto, I. (2009). Plasma fatty acid profiles in autism: A case-control study. Prostaglandins Leukotrienes and Essential Fatty Acids, 80(4), 221–227. CrossRef
- A Pilot Randomized Controlled Trial of Omega-3 Fatty Acids for Autism Spectrum Disorder
Robert L. Hendren
- Springer US